SCHEMBL3274018

SCHEMBL3274018

CCc1cc(C(=N)NO)ccc1S(=O)(=O)NCCC(=O)OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 8/20 0.39
CA14 Q9ULX7 8/20 0.39
CA7 P43166 6/20 0.38
CA9 Q16790 5/20 0.38
ALDH1A1 P00352 2/20 0.37
MAPT P10636 2/20 0.37
PRKD3 O94806 1/20 0.37
PRKCG P05129 1/20 0.37
PRKCB P05771 1/20 0.37
PRKCA P17252 1/20 0.37
PRKACA P17612 1/20 0.37
PRKACG P22612 1/20 0.37
PRKACB P22694 1/20 0.37
PRKCH P24723 1/20 0.37
PRKCI P41743 1/20 0.37
PRKCE Q02156 1/20 0.37
PRKCQ Q04759 1/20 0.37
PRKCZ Q05513 1/20 0.37
PRKCD Q05655 1/20 0.37
PRKD1 Q15139 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3274365 0.82 SMN1; SMN2 (0.46) CA12CA14CA7CA9ALDH1A1
SCHEMBL3274409 0.76 ALDH1A1 (0.43) CA12CA14CA7CA9ALDH1A1
SCHEMBL4619724 0.74 CA1 (0.35) CA12CA14CA7CA9CA2
SCHEMBL18498648 0.68 SLC6A9 (0.45) ALDH1A1MAPTCA2CA1POLB
SCHEMBL4586745 0.67 L3MBTL1 (0.40) CA12CA14CA7CA9ALDH1A1
SCHEMBL4617234 0.67 SFRP1 (0.64) CA12CA14CA7CA9ALDH1A1
SCHEMBL3103190 0.66 MEP1B (0.67) CA12CA14CA7CA9ALDH1A1
SCHEMBL7238847 0.66 PRKD3 (0.64) CA12CA14CA7CA9ALDH1A1
SCHEMBL14810783 0.65 SMN1; SMN2 (0.43) ALDH1A1SMN1; SMN2
SCHEMBL18498935 0.65 IDO1 (0.56) CA12CA14ALDH1A1CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100087491-A1 POLYCYCLIC COMPOUNDS NOVARTIS AG (CH) 2010-04-08 US disclosed
EP-2081916-A1 OXADIAZOLE DERIVATIVES WITH ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE PROPERTIES Novartis AG (CH) 2009-07-29 EP disclosed
WO-2008037476-A1 OXADIAZOLE DERIVATIVES WITH ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE PROPERTIES NOVARTIS AG (CH) 2008-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087491-A1 POLYCYCLIC COMPOUNDS CD4, HLA-DRB1, MALT1 CA12 1521/4885CA14 1179/4885CA7 3547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.